Risk of Albuminuria Higher With Dasatinib Than With Other TKIs
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
The FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Aphexda (motixafortide) is expected to be available later this month.
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.